文献速递临床试验与 GCP

点阵CO₂激光与点阵微剥脱射频治疗绝经泌尿生殖综合征:双盲随机非劣效性试验方案

Treatment of genitourinary syndrome of menopause with fractional CO₂ laser versus fractional microablative radiofrequency: study protocol for a double-blind, randomised, non-inferiority trial.
PubMed 文献 · Trials · 2026-07-03

本研究为双盲随机非劣效性试验方案,计划纳入40例绝经后泌尿生殖综合征患者,比较点阵CO₂激光与点阵微剥脱射频的疗效与安全性。主要结局为末次治疗30天后(第90天)的阴道健康指数评分。

要点

  • 比较两种非激素疗法对绝经泌尿生殖综合征的疗效与安全性。
  • 主要结局为末次治疗后30天的阴道健康指数评分。
  • 样本量40例,三次每月治疗,随访至第365天。

核心结论

  • 方案旨在比较点阵CO₂激光与点阵微剥脱射频治疗绝经泌尿生殖综合征的疗效与安全性。

研究设计与样本

  • 随机、双盲、非劣效性临床试验方案,计划纳入40例确诊绝经泌尿生殖综合征的绝经后女性。
  • 参与者随机接受点阵CO₂激光或点阵微剥脱射频,共三次每月治疗。

关键数值与推荐

  • 主要结局为末次治疗30天后(第90天)的阴道健康指数评分。
  • 次要结局包括性功能、绝经泌尿生殖综合征症状严重程度和泌尿症状。
  • 末次治疗后120天和300天(即第180天和第365天)进行随访评估。
  • 预设亚组参与者进行阴道活检组织学分析作为探索性分析。

局限性

  • 试验因注册流程行政延迟而回顾性注册,但注册前未获取、分析或使用任何结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genitourinary syndrome of menopause (GSM) affects a significant proportion of postmenopausal women, leading to symptoms such as vaginal dryness, irritation, dyspareunia, and urinary symptoms. Hormonal therapies are not suitable for all patients, particularly those with contraindications to hormone use. This study aims to compare the efficacy and safety of two non-hormonal therapies-fractional CO₂ laser (CO₂ laser) and fractional microablative radiofrequency (MAFRF)-for the treatment of GSM. METHODS: This protocol describes a randomised, double-blind, non-inferiority clinical trial that will enrol 40 postmenopausal women diagnosed with GSM. Participants will be randomised to receive either fractional CO₂ laser or fractional microablative radiofrequency in three monthly sessions. The primary outcome will be the Vaginal Health Index Score (VHIS), assessed 30 days after the last treatment session (day 90). Secondary outcomes include sexual function, GSM symptom severity, and urinary symptoms. Follow-up assessments will be conducted at 120 and 300 days after the last session (days 180 and 365, respectively). Histological analysis of vaginal biopsies will be performed in a predefined subsample of participants as an exploratory analysis. DISCUSSION: This study is expected to contribute to the comparative understanding of the efficacy and safety of CO₂ laser and MAFRF as non-hormonal therapeutic options for the treatment of GSM, potentially supporting clinical decision-making for women who are not candidates for hormonal therapy. TRIAL REGISTRATION: Brazilian Clinical Trials Registry (ReBEC): RBR-2hgwvgy. The trial was registered retrospectively due to administrative delays in the registration process. However, no outcome data were accessed, analysed, or used to inform any decisions prior to registration, and no interim analyses were performed. Additionally, no modifications were made to the study design, outcomes, or planned analyses after the initiation of data collection. Registered on July 2, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Garcia Dalbem Teles CC, Mesquita Garcia Dalbem CM, de Souza MR, et al. Treatment of genitourinary syndrome of menopause with fractional CO₂ laser versus fractional microablative radiofrequency: study protocol for a double-blind, randomised, non-inferiority trial. Trials. 2026. PMID: 42400086. doi:10.1186/s13063-026-09865-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。